Literature DB >> 10515891

Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells.

K D Jones1, Y Aoki, Y Chang, P S Moore, R Yarchoan, G Tosato.   

Abstract

Primary effusion lymphoma (PEL) is a distinct type of lymphoma associated with Kaposi's sarcoma-associated herpesvirus (KSHV) infection. To determine the factors responsible for the unrestrained proliferation of PEL, we have studied the growth factor requirements of the PEL-derived BCBL-1 and BC-1 cell lines. Both cell lines were found to be autocrine growth factor dependent and to release human interleukin-6 (IL-6), viral IL-6 (vIL-6), and human IL-10 in the culture supernatant. To establish whether these cytokines contribute to autocrine growth, neutralizing antibodies against human IL-6, vIL-6, human IL-10, and soluble IL-10 receptor were used. These experiments showed that human IL-10 and, to a lesser degree, vIL-6 serve as autocrine growth factors for BCBL-1 and BC-1 cells. Thus, human IL-10 and vIL-6 are growth factors released and used by PEL cells for autonomous proliferation and may be critical to the development and progression of PEL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515891

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  93 in total

Review 1.  Evolutionary aspects of oncogenic herpesviruses.

Authors:  J Nicholas
Journal:  Mol Pathol       Date:  2000-10

2.  The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells.

Authors:  Mark Cannon; Nicola J Philpott; Ethel Cesarman
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 3.  Cytokine homologs of human gammaherpesviruses.

Authors:  Sang-Hoon Sin; Dirk P Dittmer
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

4.  Human herpesvirus 8-encoded cytokines.

Authors:  John Nicholas
Journal:  Future Virol       Date:  2010-03       Impact factor: 1.831

5.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Authors:  Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

6.  Infection of dendritic cells by a gamma2-herpesvirus induces functional modulation.

Authors:  Emilio Flaño; Basak Kayhan; David L Woodland; Marcia A Blackman
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

7.  KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.

Authors:  Mark Cannon; Ethel Cesarman; Chris Boshoff
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

8.  Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferon-inducible protein 16-mediated inflammasomes.

Authors:  Vivek Vikram Singh; Nagaraj Kerur; Virginie Bottero; Sujoy Dutta; Sayan Chakraborty; Mairaj Ahmed Ansari; Nitika Paudel; Leela Chikoti; Bala Chandran
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects.

Authors:  C Liu; Y Okruzhnov; H Li; J Nicholas
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  The KSHV viral interleukin-6 is not essential for latency or lytic replication in BJAB cells.

Authors:  Lei Chen; Michael Lagunoff
Journal:  Virology       Date:  2006-10-30       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.